Investigating the role of indole and quinazolinone-based hybrid analogues with ketoamide fragment and alkyl extension for potential PL inhibition

Nandi, Arijit; Auti, Prashant S.; Jagtap, Utkarsh A.; Paul, Atish T.

doi:10.1016/j.molstruc.2023.137337

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…have been explored as PL inhibitor for the management of obesity. [24][25][26][27][28][29] TZD core was selected due to its structural feature resemblance to the orlistat as it contains diamide linkage, which imparts potential PL inhibitory activity and the literature reports also showed its crucial role in the management of obesity by reducing the absorption of dietary fats through inhibition of PL. Various researchers reported the potential of TZD, Prashant Dhiman et al and Ginson George et al also explored the potential of TZD derivatives i. e. compound B and D in vivo and reported their glucose lowering, total cholesterol lowering and lipid profile lowering activity as depicted in Figure 1.…”

Section: Introductionmentioning

confidence: 99%

Identification of Novel Thiazolidinedione Based Pancreatic Lipase Inhibitors for the Management of Obesity Using In Silico Approach

Khator,

Singh,

Asati

et al. 2024

ChemistrySelect

View full text Add to dashboard Cite

Accumulation of excessive fat in the body is an indication of obesity, which is becoming an alarming health concern around the world. Pancreatic lipase has been found to have a promising role in the digestion of dietary fats thereby inhibition of pancreatic lipase can be a therapeutic strategy for the management of obesity. Literature showed the anti‐pancreatic lipase potential of thiazolidinediones thereby the current study is designed to identify substituted thiazolidinedione‐based molecules as pancreatic lipase inhibitors. A 3D QSAR model with R2 value of 0.7283 and Stability of 0.843 was generated to determine the nature of substitution necessary for the inhibitory activity. Based on the generated 3D QSAR, the activity of 352 novel‐designed molecules was predicted and further screened through pharmacokinetic parameters. These compounds were docked into the binding site of the pancreatic lipase which led to the identification of 14 hit molecules with dock score between −9.523 to −7.604 kcal/mol. The molecular simulation studies and free energy calculation of the hit compounds i. e. 87 and 80 revealed good stability and binding in the active site of pancreatic lipase. The current study provides 14 hit molecules, which can be synthesized and further evaluated to explore their anti‐pancreatic lipase inhibitory activity.

show abstract